Tragara Pharmaceuticals Financing
Tragara Pharmaceuticals, Inc., Corporation just had published form D for $5.44 million equity financing. This is a new filing. Tragara Pharmaceuticals was able to sell $3.26 million so far. That is 60.00% of the financing offer. The total private offering amount was $5.44 million. The financing document was filed on 2016-11-15. The reason for the financing was: unspecified. The fundraising still has about $2.17 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Tragara Pharmaceuticals is based in California. The filler’s business is Pharmaceuticals. The D form was signed by Thomas M Estok President and Chief Executive Officer. The company was incorporated more than five years ago. The filler’s address is: 3152 Lionshead Avenue, Carlsbad, Ca, California, 92010. Thomas M. Estok is the related person in the form and it has address: C/O Tragara Pharmaceuticals, Inc., 3152 Lionshead Avenue, Carlsbad, Ca, California, 92010. Link to Tragara Pharmaceuticals Filing: 000114036116086754.
Analysis of Tragara Pharmaceuticals Offering
On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering size. Tragara Pharmaceuticals sold 60.00% of the offering. The fundraising is still open. The average investment size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 486.57% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Tragara Pharmaceuticals Also
The Form D signed by Thomas M Estok might help Tragara Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.